Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMAND: Defactinib in Malignant Pleural Mesothelioma
NCT01870609Phase 2Terminated
- Sponsor
- Verastem Oncology
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in malignant pleural mesothelioma (MPM) comparing Defactinib with Placebo (2 arms). Primary endpoints: Overall Survival and Progression-Free Survival. Started Sep 2013; status: terminated.
02
Drugs
defactinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01870609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870609.